Although some studies have shown that intestinal microbiota-derived SCFAs have beneficial glucose metabolic effects [32,33], according to a study by Vishal et al. [34], increased propionate produced by gut microbiota and transported to the liver through the portal vein controls metabolic disorders in Toll-like receptor 5-deficient mice. Here, TLR5 is linked to metabolic disease.